A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

Excluded: TP53 mutation

MCL with known TP53 mutation [excluded]

Must have received: systemic therapy

Received at least 2 prior systemic therapies (or at least 1 prior therapy for patients with WM or PCNSL) and have no other therapies known to provide clinical benefit

Must have received: BTK inhibitor — CLL/SLL, MCL, WM

CLL/SLL whose disease has failed treatment with a BTKi; MCL whose disease has failed treatment with BTKi and an anti-CD20 mAb-based regimen; WM whose disease has failed treatment with a BTKi

Must have received: anti-CD20 mAb-based regimen — MCL, FL, MZL, DLBCL

MCL whose disease has failed treatment with BTKi and an anti-CD20 mAb-based regimen; FL or MZL whose disease has failed treatment with an anti-CD20 mAb-based regimen; DLBCL whose disease has failed treatment with an anti-CD20 mAb-based regimen

Must have received: anthracycline-based regimen — DLBCL

DLBCL whose disease has failed treatment with an anti-CD20 mAb-based regimen and either: an anthracycline-based regimen; or an anti-CD19-based regimen, or another/ palliative regimen (either progressed post stem cell transplant or transplant-ineligible)

Must have received: anti-CD19-based regimen — DLBCL

DLBCL whose disease has failed treatment with an anti-CD19-based regimen

Must have received: stem cell transplant — DLBCL

DLBCL whose disease has failed treatment with ... another/ palliative regimen (either progressed post stem cell transplant or transplant-ineligible)